Cost-effectiveness of PARP inhibitors for maintenance therapy of patients with a BRCA mutation and primary epithelial ovarian cancer in China

Author:

Yang Haoran1ORCID,Zhao Qian2,Yang Yunzhi1,Lv Qianzhou1,Li Xiaoyu1

Affiliation:

1. Zhongshan Hospital Fudan University

2. University of York

Abstract

Abstract

Background Maintenance therapy with poly (ADP-ribose) polymerase inhibitors (PARPis) plays a crucial role in managing primary epithelial ovarian cancer (OC), especially in patients with a BRCA mutation. However, there is a lack of economic evaluation comparing various PARPis. Aim This study aimed to investigate the cost-effectiveness of fuzuloparib compared to routine surveillance, olaparib, niraparib, and olaparib plus bevacizumab for maintenance therapy of patients with a BRCA mutation and primary epithelial OC in China. Method A cost-effectiveness model was constructed in Microsoft Excel®, predominantly based on the data derived from FZOCUS-1, SOLO-1, PRIME, and PAOLA-1 trials. The proportion of disease-free patients alongside the 24-month model horizon was estimated by parameterizing the reconstructed patient-level data, which was digitized from the publicly available Kaplan-Meier progression-free survival (PFS) estimators. Unit costs for both health resource utilization and adverse event (AE) management were systematically sourced from peer-reviewed literature and authoritative official websites. An annual discount rate of 5% was used for both costs and PFS-life years (PFS-LY). Sensitivity analyses (SA) were performed to explore the parameter uncertainties. Results The base-case incremental cost-effectiveness ratios (ICER) were ¥1,130,845/PFS-LY, ¥602,152/PFS-LY, ¥855,688/PFS-LY, and ¥1,176,300/PFS-LY for fuzuloparib, olaparib, niraparib, and olaparib plus bevacizumab respectively. Probabilistic sensitivity analysis (PSA) confirms the robustness of these findings to parameter uncertainty. Conclusion From the perspective of the Chinese healthcare system, olaparib emerges as the most cost-effective option for maintenance therapy of patients with a BRCA mutation and primary epithelial OC, followed by niraparib, then fuzuloparib, while olaparib plus bevacizumab ranks as the least cost-effective.

Publisher

Research Square Platform LLC

Reference34 articles.

1. Burden of ovarian cancer in China from 1990 to 2030: A systematic analysis and comparison with the global level;Wang Y;Front Public Health,2023

2. NCCN clinical practice guidelines in oncology (NCCN guidelines®): ovarian cancer including fallopian tube cancer and primary peritoneal cancer;National Comprehensive Cancer Network (NCCN),2024

3. Small cell cancers of the female genital tract: Molecular and clinical aspects;Patibandla JR;Gynecol Oncol,2018

4. Epithelial ovarian cancer;Lheureux S;Lancet,2019

5. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance;Rose M;Front Cell Dev Biol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3